NEW YORK, NY / ACCESSWIRE / August 18, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm
focused on smallcap and microcap public companies, today announced it has issued an update note on BioSig Technologies, Inc.
(OTCQB: BSGM).
The report is available here: BSGM August 2016 Update Note.
"We see the publication as a major milestone for BioSig, introducing the technology to the industry through research conducted
with the Mayo Clinic, one of the most prestigious institutions in medicine. We see the article as evidence management is making
progress on its stated goals for 2016, and we are looking forward to additional peer-reviewed journals and industry presentations
in the future," commented Ajay Tandon, CEO of SeeThruEquity.
Additional highlights from the update include the following:
BioSig achieves major milestone with publication along with Mayo Clinic in leading peer-reviewed publication JACC
BioSig management had stated in an annual letter to investors and stakeholders that it would be introducing the PURE EP System™
to leading industry participants in 2016, and the company continues to follow through on this commitment. In early August, BioSig
announced that its lead device, the PURE EP System™, was featured in a research article by researchers from the prestigious Mayo
Clinic that was published in The Journal of the American College of Cardiology (JACC): Clinical Electrophysiology, a leading
peer-reviewed publication focused on care and heart health in the area of cardiac electrophysiology. Authored by Dr. Samuel
Asirvatham, Vice Chair of Cardiovascular Diseases and program director of Clinical Cardiac Electrophysiology Training Program at
the Mayo Clinic in Rochester, MN, the article represents the first piece about PURE EP™ in a peer-reviewed publication and is a
significant milestone for the company.
Article highlights advantages versus standard EP recording systems
BioSig's PURE EP System is a high fidelity surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis
system, which is designed to improve the process of identifying catheter ablation targets - areas of tissue to destroy that
otherwise create a cardiac arrhythmia. The article appearing in JACC: Clinical Electrophysiology featuring BioSig's PURE EP™ was
entitled "Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other
High-Frequency Signals" and highlighted the advantages of BioSig's proprietary PURE EP™ technology versus standard EP recording
systems, particularly for the analysis of high frequency signals (ie, Purkinjie potentials). Dr. Asirvatham also noted PURE EP's
capability to show the same channel with different processing options, enabling doctors to highlight specific features while still
displaying the original electrogram signal. In our view, the article is a major event for the company, providing peer-reviewed
journal validation for the company's innovative approach to a $3.5 billion market opportunity while elevating its profile and
garner increased industry attention to the advantages of the PURE EP™ System.
Maintain price target of $3.53 for BioSig
We have been encouraged by the progress made by BioSig since our initiation of coverage in February 2016 and note that shares
have risen by more than 25% in that time. We see several opportunities ahead for BioSig and are maintaining a price target of $3.53
at this time.
Please review important disclosures at www.seethruequity.com.
About BioSig Technologies, Inc.
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $3
billion electrophysiology (EP) marketplace1 (www.biosigtech.com). Led by a proven management team and a veteran, independent Board
of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist
electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings
and providing clarity of data which may be used to guide the EPs in identifying ablation targets -- areas of tissue to treat that
otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in
2012 to $5.5 billion by 20191 -- making it one of the fastest growing medical device segments. Just in the US, the number of Atrial
Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 20172.
BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through
UCLA labs, and has performed pre-clinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the
nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center,
and Mayo Clinic.
1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left
atrial tachycardia, left WPW, left atrial flutter.
About SeeThruEquity
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on
underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is
not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly
traded companies with market capitalizations less than $1 billion.
SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading
estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive
databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York
City.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon SeeThruEquity info@seethruequity.com
SOURCE: SeeThruEquity
